Axsome Therapeutics, Inc. (AXSM) 10-Year Financial Performance & Capital Metrics

AXSM • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Show more

Revenue $386M +42.5%
EBITDA -$273M -21.2%
Net Income -$287M -20.1%
EPS (Diluted) -5.99 -13.7%
Gross Margin 91.37% +1.1%
EBITDA Margin -70.68% +15.0%
Operating Margin -72.74% +15.1%
Net Margin -74.47% +15.8%
ROE -231.63% -45.5%
ROIC -
Debt/Equity 3.38 +246.8%
Interest Coverage -42.71 -18.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 3.4x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Expensive at 148.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM65.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM28.48%

ROCE

10Y Avg-93.52%

5Y Avg-84.79%

3Y Avg-86.33%

Latest-71.23%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	50.04M	270.6M	385.69M
Revenue Growth %	-	-	-	-	-	-	-	-	4.41%	0.43%
Cost of Goods Sold+	3.54K	20.48K	42.56K	48.94K	37.33K	0	0	5.2M	26.07M	33.3M
COGS % of Revenue	-	-	-	-	-	-	-	0.1%	0.1%	0.09%
Gross Profit+	-3.54K	-20.48K	-42.56K	-48.94K	-37.33K	0	0	44.84M	244.53M	352.39M
Gross Margin %	-	-	-	-	-	-	-	0.9%	0.9%	0.91%
Gross Profit Growth %	-	-4.78%	-1.08%	-0.15%	0.24%	1%	-	-	4.45%	0.44%
Operating Expenses+	9.2M	27.54M	27.16M	32.85M	67.11M	99.14M	124.71M	224.64M	476.36M	632.95M
OpEx % of Revenue	-	-	-	-	-	-	-	4.49%	1.76%	1.64%
Selling, General & Admin	2.42M	6.34M	7.21M	9.35M	13.6M	28.9M	66.65M	159.25M	323.12M	411.36M
SG&A % of Revenue	-	-	-	-	-	-	-	3.18%	1.19%	1.07%
Research & Development	6.78M	21.2M	19.96M	23.5M	53.65M	70.24M	58.06M	57.95M	97.94M	187.08M
R&D % of Revenue	-	-	-	-	-	-	-	1.16%	0.36%	0.49%
Other Operating Expenses	0	0	0	0	-139.45K	-53.58K	0	7.44M	55.29M	34.52M
Operating Income+	-9.2M	-27.54M	-27.16M	-32.85M	-67.25M	-99.14M	-124.71M	-179.8M	-231.82M	-280.56M
Operating Margin %	-	-	-	-	-	-	-	-3.59%	-0.86%	-0.73%
Operating Income Growth %	-0.62%	-2%	0.01%	-0.21%	-1.05%	-0.47%	-0.26%	-0.44%	-0.29%	-0.21%
EBITDA+	-9.19M	-27.52M	-27.12M	-32.8M	-67.21M	-99.06M	-124.63M	-175.4M	-224.99M	-272.6M
EBITDA Margin %	-	-	-	-	-	-	-	-3.51%	-0.83%	-0.71%
EBITDA Growth %	-2.35%	-1.99%	0.01%	-0.21%	-1.05%	-0.47%	-0.26%	-0.41%	-0.28%	-0.21%
D&A (Non-Cash Add-back)	3.54K	20.48K	42.56K	48.94K	37.33K	77.72K	76K	4.4M	6.83M	7.96M
EBIT	-9.2M	-27.54M	-27.81M	-32.63M	-67.25M	-100.39M	-124.71M	-179.8M	-231.82M	-280.56M
Net Interest Income+	0	-132.42K	-1.34M	-1.13M	0	0	-5.7M	-7.33M	-6.45M	-6.57M
Interest Income	914.95K	0	0	0	1.24M	2.57M	0	0	0	0
Interest Expense	914.95K	132.42K	1.34M	1.13M	1.24M	2.57M	5.7M	7.33M	6.45M	6.57M
Other Income/Expense	-1.36M	341.86K	-1.78M	1.66M	-1.1M	-3.76M	-5.7M	-7.33M	-6.45M	-6.57M
Pretax Income+	-10.56M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-238.28M	-287.13M
Pretax Margin %	-	-	-	-	-	-	-	-3.74%	-0.88%	-0.74%
Income Tax+	1.36M	0	0	0	0	0	0	0	960K	85K
Effective Tax Rate %	1.16%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.21M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Net Margin %	-	-	-	-	-	-	-	-3.74%	-0.88%	-0.74%
Net Income Growth %	-1.03%	-1.23%	-0.06%	-0.07%	-1.21%	-0.51%	-0.27%	-0.44%	-0.28%	-0.2%
Net Income (Continuing)	-12.21M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-1.42	-1.27	-1.15	-2.05	-2.83	-3.47	-4.60	-5.27	-5.99
EPS Growth %	-0.87%	-0.61%	0.11%	0.09%	-0.78%	-0.38%	-0.23%	-0.33%	-0.15%	-0.14%
EPS (Basic)	-0.88	-1.42	-1.27	-1.15	-2.05	-2.83	-3.47	-4.60	-5.27	-5.99
Diluted Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Basic Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49.03M	38M	35.3M	15.22M	220.38M	184.02M	86.52M	245.64M	504.26M	485.06M
Cash & Short-Term Investments	48.04M	36.62M	34.02M	13.97M	219.97M	183.88M	86.47M	200.84M	386.19M	315.35M
Cash Only	48.04M	36.62M	34.02M	13.97M	219.97M	183.88M	86.47M	200.84M	386.19M	315.35M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	37.7M	94.82M	142M
Days Sales Outstanding	-	-	-	-	-	-	-	275	127.9	134.38
Inventory	0	0	0	0	0	0	0	4.32M	15.13M	15.73M
Days Inventory Outstanding	-	-	-	-	-	-	-	303.35	211.94	172.42
Other Current Assets	0	0	0	0	0	0	0	2.78M	8.12M	11.98M
Total Non-Current Assets+	43.28K	213.55K	256.02K	164.18K	170.5K	2.11M	1.27M	85.83M	83.97M	83.43M
Property, Plant & Equipment	16.65K	100.73K	68.07K	51.83K	30.62K	1.79M	944.01K	1.14M	7.62M	5.97M
Fixed Asset Turnover	-	-	-	-	-	-	-	43.82x	35.52x	64.64x
Goodwill	0	0	0	0	0	0	0	10.31M	12.04M	12.04M
Intangible Assets	0	0	0	0	0	0	0	59.66M	53.29M	46.89M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	26.63K	112.82K	187.95K	112.34K	139.88K	317.38K	322.91K	14.72M	11.03M	18.53M
Total Assets+	49.08M	38.21M	35.56M	15.38M	220.55M	186.13M	87.79M	331.48M	588.24M	568.5M
Asset Turnover	-	-	-	-	-	-	-	0.15x	0.46x	0.68x
Asset Growth %	16.61%	-0.22%	-0.07%	-0.57%	13.34%	-0.16%	-0.53%	2.78%	0.77%	-0.03%
Total Current Liabilities+	2.63M	7.17M	12.18M	10.82M	24.49M	23.44M	23.07M	96.56M	138.85M	230.1M
Accounts Payable	1.89M	4.08M	3.44M	3.69M	10.94M	13.5M	13.15M	38.6M	40.68M	72M
Days Payables Outstanding	195.01K	72.72K	29.46K	27.5K	107K	-	-	2.71K	569.65	789.09
Short-Term Debt	0	269.16K	3.27M	3.29M	2.6M	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	444.29K	0	0	0	4.05M	17.18M	76.45M	36.51M
Current Ratio	18.63x	5.30x	2.90x	1.41x	9.00x	7.85x	3.75x	2.54x	3.63x	2.11x
Quick Ratio	18.63x	5.30x	2.90x	1.41x	9.00x	7.85x	3.75x	2.50x	3.52x	2.04x
Cash Conversion Cycle	-	-	-	-	-	-	-	-2.13K	-229.81	-482.28
Total Non-Current Liabilities+	0	9.47M	6.66M	3.62M	17.33M	48.9M	49.09M	125.36M	258.4M	281.38M
Long-Term Debt	0	9.47M	6.66M	3.62M	17.33M	48.32M	49.09M	94.26M	178.07M	180.71M
Capital Lease Obligations	0	0	0	0	0	581.71K	0	0	7.04M	8.99M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	31.1M	73.3M	91.68M
Total Liabilities	2.63M	16.64M	18.84M	14.44M	41.83M	72.34M	72.15M	221.92M	397.26M	511.48M
Total Debt+	0	9.74M	9.93M	6.91M	19.93M	50.12M	49.71M	94.68M	186.37M	192.96M
Net Debt	-48.04M	-26.88M	-24.09M	-7.06M	-200.03M	-133.75M	-36.76M	-106.16M	-199.82M	-122.4M
Debt / Equity	-	0.45x	0.59x	7.37x	0.11x	0.44x	3.18x	0.86x	0.98x	3.38x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.05x	-207.99x	-20.27x	-29.14x	-54.25x	-38.64x	-21.89x	-24.51x	-35.93x	-42.71x
Total Equity+	46.44M	21.57M	16.72M	937.92K	178.72M	113.79M	15.63M	109.56M	190.98M	57.02M
Equity Growth %	15.5%	-0.54%	-0.23%	-0.94%	189.55%	-0.36%	-0.86%	6.01%	0.74%	-0.7%
Book Value per Share	3.89	1.13	0.73	0.03	5.25	3.06	0.42	2.69	4.20	1.19
Total Shareholders' Equity	46.44M	21.57M	16.72M	937.92K	178.72M	113.79M	15.63M	109.56M	190.98M	57.02M
Common Stock	1.92K	1.92K	2.55K	3.01K	3.69K	3.74K	3.78K	4K	5K	5K
Retained Earnings	-20.44M	-47.64M	-76.58M	-107.55M	-175.9M	-278.8M	-409.2M	-596.33M	-835.57M	-1.12B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.44M	-21.28M	-26.47M	-30.05M	-46.38M	-78.46M	-108.23M	-116.51M	-145.08M	-128.41M
Operating CF Margin %	-	-	-	-	-	-	-	-2.33%	-0.54%	-0.33%
Operating CF Growth %	-0.62%	-1.86%	-0.24%	-0.14%	-0.54%	-0.69%	-0.38%	-0.08%	-0.25%	0.11%
Net Income	-10.56M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Depreciation & Amortization	3.54K	20.48K	42.56K	48.94K	37.33K	77.72K	76K	4.4M	6.83M	0
Stock-Based Compensation	803.28K	2.03M	2.07M	1.75M	6.12M	14.76M	20.8M	37.73M	62.62M	85.22M
Deferred Taxes	2.28M	0	646K	-2.79M	0	1.25M	0	0	0	0
Other Non-Cash Items	-902.22K	68.93K	470.52K	375.63K	649.99K	7.95M	974K	4.83M	53.1M	39.69M
Working Capital Changes	937.73K	3.8M	-759.55K	1.52M	15.17M	412.04K	324K	23.67M	-28.39M	33.9M
Change in Receivables	0	0	0	0	0	177.5K	0	-37.7M	-57.12M	-47.18M
Change in Inventory	0	0	0	0	0	-177.5K	-6K	-5.28M	-8.16M	744K
Change in Payables	1.13M	2.19M	-645.72K	251.79K	7.26M	2.56M	-355K	25.46M	2.07M	31.32M
Cash from Investing+	-20.2K	-104.56K	-9.9K	-32.7K	-16.12K	-45.89K	-308K	-53.7M	-582K	-270K
Capital Expenditures	-20.2K	-104.56K	-9.9K	-32.7K	-16.12K	-45.89K	-308K	-702K	-582K	-270K
CapEx % of Revenue	-	-	-	-	-	-	-	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	52.88M	9.97M	23.88M	10.03M	252.39M	42.41M	11.13M	284.58M	331.01M	57.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-12.49K	-64.93K	484.61K	486.03K	1.39M	-52.76K	3.69M	-4.18M	-12.74M	18.05M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.46M	-21.39M	-26.48M	-30.09M	-46.39M	-78.5M	-108.53M	-117.21M	-145.66M	-128.68M
FCF Margin %	-	-	-	-	-	-	-	-2.34%	-0.54%	-0.33%
FCF Growth %	-0.62%	-1.87%	-0.24%	-0.14%	-0.54%	-0.69%	-0.38%	-0.08%	-0.24%	0.12%
FCF per Share	-0.62	-1.12	-1.16	-1.12	-1.36	-2.11	-2.89	-2.88	-3.21	-2.69
FCF Conversion (FCF/Net Income)	0.61x	0.78x	0.91x	0.97x	0.68x	0.76x	0.83x	0.62x	0.61x	0.45x
Interest Paid	0	0	0	0	0	0	4.63M	7.69M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-56.48%	-79.99%	-151.19%	-350.78%	-76.08%	-70.36%	-201.51%	-298.97%	-159.21%	-231.63%
Gross Margin	-	-	-	-	-	-	-	89.61%	90.37%	91.37%
Net Margin	-	-	-	-	-	-	-	-373.99%	-88.41%	-74.47%
Debt / Equity	-	0.45x	0.59x	7.37x	0.11x	0.44x	3.18x	0.86x	0.98x	3.38x
Interest Coverage	-10.05x	-207.99x	-20.27x	-29.14x	-54.25x	-38.64x	-21.89x	-24.51x	-35.93x	-42.71x
FCF Conversion	0.61x	0.78x	0.91x	0.97x	0.68x	0.76x	0.83x	0.62x	0.61x	0.45x
Revenue Growth	-	-	-	-	-	-	-	-	440.8%	42.53%

Revenue by Segment

	2022	2023	2024
Product	-	202.46M	381.68M
Product Growth	-	-	88.52%
License	-	65.73M	-
License Growth	-	-	-
Royalty	-	2.4M	-
Royalty Growth	-	-	-

Revenue by Geography

	2022	2023	2024
UNITED STATES	49.13M	197.22M	378.16M
UNITED STATES Growth	-	301.42%	91.74%
Non-US	905K	65.73M	4.02M
Non-US Growth	-	7163.54%	-93.89%

Frequently Asked Questions

Growth & Financials

Axsome Therapeutics, Inc. (AXSM) reported $561.3M in revenue for fiscal year 2024.

Axsome Therapeutics, Inc. (AXSM) grew revenue by 42.5% over the past year. This is strong growth.

Axsome Therapeutics, Inc. (AXSM) reported a net loss of $229.5M for fiscal year 2024.

Dividend & Returns

Axsome Therapeutics, Inc. (AXSM) has a return on equity (ROE) of -231.6%. Negative ROE indicates the company is unprofitable.

Axsome Therapeutics, Inc. (AXSM) had negative free cash flow of $101.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Axsome Therapeutics, Inc. (AXSM) 10-Year Financial Performance & Capital Metrics

AXSM • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $386M +42.5%
EBITDA -$273M -21.2%
Net Income -$287M -20.1%
EPS (Diluted) -5.99 -13.7%
Gross Margin 91.37% +1.1%
EBITDA Margin -70.68% +15.0%
Operating Margin -72.74% +15.1%
Net Margin -74.47% +15.8%
ROE -231.63% -45.5%
ROIC -
Debt/Equity 3.38 +246.8%
Interest Coverage -42.71 -18.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 86 (top 14%)
✓Trading near 52-week high

✗Weaknesses

✗High debt to equity ratio of 3.4x
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Expensive at 148.8x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM65.83%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM28.48%

ROCE

10Y Avg-93.52%

5Y Avg-84.79%

3Y Avg-86.33%

Latest-71.23%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.54B	26.86	19.75	31.85%	24.94%	28.47%	3.46%	0.07
JAZZJazz Pharmaceuticals plc	10.38B	170.81	19.75	6.12%	-8.86%	-9.31%	12.99%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.85B	23.17	17.69	23.49%	37.63%	23.64%	8.4%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.08B	36.04	14.36	22.8%	22.48%	22.23%	10.53%	0.28
ALKSAlkermes plc	5.06B	30.62	14.11	-6.36%	22.27%	19.55%	8.02%	0.05
PRTCPureTech Health plc	458.47M	18.97	9.49	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	489.79M	19.36	-1.09
NMRANeumora Therapeutics, Inc. Common Stock	365.37M	2.15	-1.41			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	50.04M	270.6M	385.69M
Revenue Growth %	-	-	-	-	-	-	-	-	4.41%	0.43%
Cost of Goods Sold+	3.54K	20.48K	42.56K	48.94K	37.33K	0	0	5.2M	26.07M	33.3M
COGS % of Revenue	-	-	-	-	-	-	-	0.1%	0.1%	0.09%
Gross Profit+	-3.54K	-20.48K	-42.56K	-48.94K	-37.33K	0	0	44.84M	244.53M	352.39M
Gross Margin %	-	-	-	-	-	-	-	0.9%	0.9%	0.91%
Gross Profit Growth %	-	-4.78%	-1.08%	-0.15%	0.24%	1%	-	-	4.45%	0.44%
Operating Expenses+	9.2M	27.54M	27.16M	32.85M	67.11M	99.14M	124.71M	224.64M	476.36M	632.95M
OpEx % of Revenue	-	-	-	-	-	-	-	4.49%	1.76%	1.64%
Selling, General & Admin	2.42M	6.34M	7.21M	9.35M	13.6M	28.9M	66.65M	159.25M	323.12M	411.36M
SG&A % of Revenue	-	-	-	-	-	-	-	3.18%	1.19%	1.07%
Research & Development	6.78M	21.2M	19.96M	23.5M	53.65M	70.24M	58.06M	57.95M	97.94M	187.08M
R&D % of Revenue	-	-	-	-	-	-	-	1.16%	0.36%	0.49%
Other Operating Expenses	0	0	0	0	-139.45K	-53.58K	0	7.44M	55.29M	34.52M
Operating Income+	-9.2M	-27.54M	-27.16M	-32.85M	-67.25M	-99.14M	-124.71M	-179.8M	-231.82M	-280.56M
Operating Margin %	-	-	-	-	-	-	-	-3.59%	-0.86%	-0.73%
Operating Income Growth %	-0.62%	-2%	0.01%	-0.21%	-1.05%	-0.47%	-0.26%	-0.44%	-0.29%	-0.21%
EBITDA+	-9.19M	-27.52M	-27.12M	-32.8M	-67.21M	-99.06M	-124.63M	-175.4M	-224.99M	-272.6M
EBITDA Margin %	-	-	-	-	-	-	-	-3.51%	-0.83%	-0.71%
EBITDA Growth %	-2.35%	-1.99%	0.01%	-0.21%	-1.05%	-0.47%	-0.26%	-0.41%	-0.28%	-0.21%
D&A (Non-Cash Add-back)	3.54K	20.48K	42.56K	48.94K	37.33K	77.72K	76K	4.4M	6.83M	7.96M
EBIT	-9.2M	-27.54M	-27.81M	-32.63M	-67.25M	-100.39M	-124.71M	-179.8M	-231.82M	-280.56M
Net Interest Income+	0	-132.42K	-1.34M	-1.13M	0	0	-5.7M	-7.33M	-6.45M	-6.57M
Interest Income	914.95K	0	0	0	1.24M	2.57M	0	0	0	0
Interest Expense	914.95K	132.42K	1.34M	1.13M	1.24M	2.57M	5.7M	7.33M	6.45M	6.57M
Other Income/Expense	-1.36M	341.86K	-1.78M	1.66M	-1.1M	-3.76M	-5.7M	-7.33M	-6.45M	-6.57M
Pretax Income+	-10.56M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-238.28M	-287.13M
Pretax Margin %	-	-	-	-	-	-	-	-3.74%	-0.88%	-0.74%
Income Tax+	1.36M	0	0	0	0	0	0	0	960K	85K
Effective Tax Rate %	1.16%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.21M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Net Margin %	-	-	-	-	-	-	-	-3.74%	-0.88%	-0.74%
Net Income Growth %	-1.03%	-1.23%	-0.06%	-0.07%	-1.21%	-0.51%	-0.27%	-0.44%	-0.28%	-0.2%
Net Income (Continuing)	-12.21M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.88	-1.42	-1.27	-1.15	-2.05	-2.83	-3.47	-4.60	-5.27	-5.99
EPS Growth %	-0.87%	-0.61%	0.11%	0.09%	-0.78%	-0.38%	-0.23%	-0.33%	-0.15%	-0.14%
EPS (Basic)	-0.88	-1.42	-1.27	-1.15	-2.05	-2.83	-3.47	-4.60	-5.27	-5.99
Diluted Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Basic Shares Outstanding	11.95M	19.15M	22.76M	26.88M	34.02M	37.21M	37.62M	40.66M	45.43M	47.91M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49.03M	38M	35.3M	15.22M	220.38M	184.02M	86.52M	245.64M	504.26M	485.06M
Cash & Short-Term Investments	48.04M	36.62M	34.02M	13.97M	219.97M	183.88M	86.47M	200.84M	386.19M	315.35M
Cash Only	48.04M	36.62M	34.02M	13.97M	219.97M	183.88M	86.47M	200.84M	386.19M	315.35M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	37.7M	94.82M	142M
Days Sales Outstanding	-	-	-	-	-	-	-	275	127.9	134.38
Inventory	0	0	0	0	0	0	0	4.32M	15.13M	15.73M
Days Inventory Outstanding	-	-	-	-	-	-	-	303.35	211.94	172.42
Other Current Assets	0	0	0	0	0	0	0	2.78M	8.12M	11.98M
Total Non-Current Assets+	43.28K	213.55K	256.02K	164.18K	170.5K	2.11M	1.27M	85.83M	83.97M	83.43M
Property, Plant & Equipment	16.65K	100.73K	68.07K	51.83K	30.62K	1.79M	944.01K	1.14M	7.62M	5.97M
Fixed Asset Turnover	-	-	-	-	-	-	-	43.82x	35.52x	64.64x
Goodwill	0	0	0	0	0	0	0	10.31M	12.04M	12.04M
Intangible Assets	0	0	0	0	0	0	0	59.66M	53.29M	46.89M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	26.63K	112.82K	187.95K	112.34K	139.88K	317.38K	322.91K	14.72M	11.03M	18.53M
Total Assets+	49.08M	38.21M	35.56M	15.38M	220.55M	186.13M	87.79M	331.48M	588.24M	568.5M
Asset Turnover	-	-	-	-	-	-	-	0.15x	0.46x	0.68x
Asset Growth %	16.61%	-0.22%	-0.07%	-0.57%	13.34%	-0.16%	-0.53%	2.78%	0.77%	-0.03%
Total Current Liabilities+	2.63M	7.17M	12.18M	10.82M	24.49M	23.44M	23.07M	96.56M	138.85M	230.1M
Accounts Payable	1.89M	4.08M	3.44M	3.69M	10.94M	13.5M	13.15M	38.6M	40.68M	72M
Days Payables Outstanding	195.01K	72.72K	29.46K	27.5K	107K	-	-	2.71K	569.65	789.09
Short-Term Debt	0	269.16K	3.27M	3.29M	2.6M	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	444.29K	0	0	0	4.05M	17.18M	76.45M	36.51M
Current Ratio	18.63x	5.30x	2.90x	1.41x	9.00x	7.85x	3.75x	2.54x	3.63x	2.11x
Quick Ratio	18.63x	5.30x	2.90x	1.41x	9.00x	7.85x	3.75x	2.50x	3.52x	2.04x
Cash Conversion Cycle	-	-	-	-	-	-	-	-2.13K	-229.81	-482.28
Total Non-Current Liabilities+	0	9.47M	6.66M	3.62M	17.33M	48.9M	49.09M	125.36M	258.4M	281.38M
Long-Term Debt	0	9.47M	6.66M	3.62M	17.33M	48.32M	49.09M	94.26M	178.07M	180.71M
Capital Lease Obligations	0	0	0	0	0	581.71K	0	0	7.04M	8.99M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	31.1M	73.3M	91.68M
Total Liabilities	2.63M	16.64M	18.84M	14.44M	41.83M	72.34M	72.15M	221.92M	397.26M	511.48M
Total Debt+	0	9.74M	9.93M	6.91M	19.93M	50.12M	49.71M	94.68M	186.37M	192.96M
Net Debt	-48.04M	-26.88M	-24.09M	-7.06M	-200.03M	-133.75M	-36.76M	-106.16M	-199.82M	-122.4M
Debt / Equity	-	0.45x	0.59x	7.37x	0.11x	0.44x	3.18x	0.86x	0.98x	3.38x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.05x	-207.99x	-20.27x	-29.14x	-54.25x	-38.64x	-21.89x	-24.51x	-35.93x	-42.71x
Total Equity+	46.44M	21.57M	16.72M	937.92K	178.72M	113.79M	15.63M	109.56M	190.98M	57.02M
Equity Growth %	15.5%	-0.54%	-0.23%	-0.94%	189.55%	-0.36%	-0.86%	6.01%	0.74%	-0.7%
Book Value per Share	3.89	1.13	0.73	0.03	5.25	3.06	0.42	2.69	4.20	1.19
Total Shareholders' Equity	46.44M	21.57M	16.72M	937.92K	178.72M	113.79M	15.63M	109.56M	190.98M	57.02M
Common Stock	1.92K	1.92K	2.55K	3.01K	3.69K	3.74K	3.78K	4K	5K	5K
Retained Earnings	-20.44M	-47.64M	-76.58M	-107.55M	-175.9M	-278.8M	-409.2M	-596.33M	-835.57M	-1.12B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.44M	-21.28M	-26.47M	-30.05M	-46.38M	-78.46M	-108.23M	-116.51M	-145.08M	-128.41M
Operating CF Margin %	-	-	-	-	-	-	-	-2.33%	-0.54%	-0.33%
Operating CF Growth %	-0.62%	-1.86%	-0.24%	-0.14%	-0.54%	-0.69%	-0.38%	-0.08%	-0.25%	0.11%
Net Income	-10.56M	-27.2M	-28.94M	-30.97M	-68.35M	-102.9M	-130.4M	-187.13M	-239.24M	-287.22M
Depreciation & Amortization	3.54K	20.48K	42.56K	48.94K	37.33K	77.72K	76K	4.4M	6.83M	0
Stock-Based Compensation	803.28K	2.03M	2.07M	1.75M	6.12M	14.76M	20.8M	37.73M	62.62M	85.22M
Deferred Taxes	2.28M	0	646K	-2.79M	0	1.25M	0	0	0	0
Other Non-Cash Items	-902.22K	68.93K	470.52K	375.63K	649.99K	7.95M	974K	4.83M	53.1M	39.69M
Working Capital Changes	937.73K	3.8M	-759.55K	1.52M	15.17M	412.04K	324K	23.67M	-28.39M	33.9M
Change in Receivables	0	0	0	0	0	177.5K	0	-37.7M	-57.12M	-47.18M
Change in Inventory	0	0	0	0	0	-177.5K	-6K	-5.28M	-8.16M	744K
Change in Payables	1.13M	2.19M	-645.72K	251.79K	7.26M	2.56M	-355K	25.46M	2.07M	31.32M
Cash from Investing+	-20.2K	-104.56K	-9.9K	-32.7K	-16.12K	-45.89K	-308K	-53.7M	-582K	-270K
Capital Expenditures	-20.2K	-104.56K	-9.9K	-32.7K	-16.12K	-45.89K	-308K	-702K	-582K	-270K
CapEx % of Revenue	-	-	-	-	-	-	-	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	52.88M	9.97M	23.88M	10.03M	252.39M	42.41M	11.13M	284.58M	331.01M	57.84M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-12.49K	-64.93K	484.61K	486.03K	1.39M	-52.76K	3.69M	-4.18M	-12.74M	18.05M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.46M	-21.39M	-26.48M	-30.09M	-46.39M	-78.5M	-108.53M	-117.21M	-145.66M	-128.68M
FCF Margin %	-	-	-	-	-	-	-	-2.34%	-0.54%	-0.33%
FCF Growth %	-0.62%	-1.87%	-0.24%	-0.14%	-0.54%	-0.69%	-0.38%	-0.08%	-0.24%	0.12%
FCF per Share	-0.62	-1.12	-1.16	-1.12	-1.36	-2.11	-2.89	-2.88	-3.21	-2.69
FCF Conversion (FCF/Net Income)	0.61x	0.78x	0.91x	0.97x	0.68x	0.76x	0.83x	0.62x	0.61x	0.45x
Interest Paid	0	0	0	0	0	0	4.63M	7.69M	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-56.48%	-79.99%	-151.19%	-350.78%	-76.08%	-70.36%	-201.51%	-298.97%	-159.21%	-231.63%
Gross Margin	-	-	-	-	-	-	-	89.61%	90.37%	91.37%
Net Margin	-	-	-	-	-	-	-	-373.99%	-88.41%	-74.47%
Debt / Equity	-	0.45x	0.59x	7.37x	0.11x	0.44x	3.18x	0.86x	0.98x	3.38x
Interest Coverage	-10.05x	-207.99x	-20.27x	-29.14x	-54.25x	-38.64x	-21.89x	-24.51x	-35.93x	-42.71x
FCF Conversion	0.61x	0.78x	0.91x	0.97x	0.68x	0.76x	0.83x	0.62x	0.61x	0.45x
Revenue Growth	-	-	-	-	-	-	-	-	440.8%	42.53%

Revenue by Segment

	2022	2023	2024
Product	-	202.46M	381.68M
Product Growth	-	-	88.52%
License	-	65.73M	-
License Growth	-	-	-
Royalty	-	2.4M	-
Royalty Growth	-	-	-

Revenue by Geography

	2022	2023	2024
UNITED STATES	49.13M	197.22M	378.16M
UNITED STATES Growth	-	301.42%	91.74%
Non-US	905K	65.73M	4.02M
Non-US Growth	-	7163.54%	-93.89%

Frequently Asked Questions

Growth & Financials

Axsome Therapeutics, Inc. (AXSM) reported $561.3M in revenue for fiscal year 2024.

Axsome Therapeutics, Inc. (AXSM) grew revenue by 42.5% over the past year. This is strong growth.

Axsome Therapeutics, Inc. (AXSM) reported a net loss of $229.5M for fiscal year 2024.

Dividend & Returns

Axsome Therapeutics, Inc. (AXSM) has a return on equity (ROE) of -231.6%. Negative ROE indicates the company is unprofitable.

Axsome Therapeutics, Inc. (AXSM) had negative free cash flow of $101.0M in fiscal year 2024, likely due to heavy capital investments.